These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34766882)

  • 1. Phenotypic and
    Moreira JS; Galvão DS; Xavier CFC; Cunha S; Pita SSDR; Reis JN; Freitas HF
    J Biomol Struct Dyn; 2022; 40(24):14223-14235. PubMed ID: 34766882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiosemicarbazones exhibit inhibitory efficacy against New Delhi metallo-β-lactamase-1 (NDM-1).
    Ge Y; Kang PW; Li JQ; Gao H; Zhai L; Sun LY; Chen C; Yang KW
    J Antibiot (Tokyo); 2021 Sep; 74(9):574-579. PubMed ID: 34234284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroxyphenyl-substituted thiosemicarbazone: A potent scaffold for the development of metallo-β-lactamases inhibitors and antimicrobial.
    Liu L; Xu YS; Chigan JZ; Zhai L; Ding HH; Wu XR; Chen WY; Yang KW
    Bioorg Chem; 2022 Oct; 127():105928. PubMed ID: 35717802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diaryl-substituted thiosemicarbazone: A potent scaffold for the development of New Delhi metallo-β-lactamase-1 inhibitors.
    Li JQ; Sun LY; Jiang Z; Chen C; Gao H; Chigan JZ; Ding HH; Yang KW
    Bioorg Chem; 2021 Feb; 107():104576. PubMed ID: 33383326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach.
    Muteeb G; Alsultan A; Farhan M; Aatif M
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurones and derivatives as promising New Delhi metallo-β-lactamase (NDM-1) inhibitors.
    Caburet J; Verdirosa F; Moretti M; Roulier B; Simoncelli G; Haudecoeur R; Ghazi S; Jamet H; Docquier JD; Boucherle B; Peuchmaur M
    Bioorg Med Chem; 2024 Jan; 97():117559. PubMed ID: 38109811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant
    Peters BK; Reddy N; Shungube M; Girdhari L; Baijnath S; Mdanda S; Chetty L; Ntombela T; Arumugam T; Bester LA; Singh SD; Chuturgoon A; Arvidsson PI; Maguire GEM; Kruger HG; Naicker T; Govender T
    ACS Infect Dis; 2023 Mar; 9(3):486-496. PubMed ID: 36786013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,4,7-Triazacyclononane Restores the Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing
    Somboro AM; Amoako DG; Osei Sekyere J; Kumalo HM; Khan R; Bester LA; Essack SY
    Appl Environ Microbiol; 2019 Feb; 85(3):. PubMed ID: 30478231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel metallo-β-lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo-lactamase-1 (NDM-1)-harbouring bacteria.
    Guo Y; Liu H; Yang M; Ding R; Gao Y; Niu X; Deng X; Wang J; Feng H; Qiu J
    Br J Pharmacol; 2024 Jan; 181(1):54-69. PubMed ID: 37539785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten Years with New Delhi Metallo-β-lactamase-1 (NDM-1): From Structural Insights to Inhibitor Design.
    Linciano P; Cendron L; Gianquinto E; Spyrakis F; Tondi D
    ACS Infect Dis; 2019 Jan; 5(1):9-34. PubMed ID: 30421910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
    Li JQ; Gao H; Zhai L; Sun LY; Chen C; Chigan JZ; Ding HH; Yang KW
    Bioorg Med Chem; 2021 May; 38():116128. PubMed ID: 33862468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor discovery of full-length New Delhi metallo-β-lactamase-1 (NDM-1).
    Shen B; Yu Y; Chen H; Cao X; Lao X; Fang Y; Shi Y; Chen J; Zheng H
    PLoS One; 2013; 8(5):e62955. PubMed ID: 23675445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Throughput Virtual Screening, Molecular Dynamics Simulation, and Enzyme Kinetics Identified ZINC84525623 as a Potential Inhibitor of NDM-1.
    Rehman MT; AlAjmi MF; Hussain A; Rather GM; Khan MA
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Potential Inhibitor (MCULE-8777613195-0-12) of New Delhi Metallo-β-Lactamase-1 (NDM-1) Using In Silico and In Vitro Approaches.
    Muteeb G; Rehman MT; AlAjmi MF; Aatif M; Farhan M; Shafi S
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144666
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Cheepurupalli L; Diaz A; Gopal AC; Rathore SS; Ramakrishnan V; Ramakrishnan J
    J Biomol Struct Dyn; 2022; 40(24):13593-13605. PubMed ID: 34657563
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Vasudevan A; Kesavan DK; Wu L; Su Z; Wang S; Ramasamy MK; Hopper W; Xu H
    Biomed Res Int; 2022; 2022():4230788. PubMed ID: 35372567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad-Spectrum Inhibitors against Class A, B, and C Type β-Lactamases to Block the Hydrolysis against Antibiotics: Kinetics and Structural Characterization.
    Farhat N; Gupta D; Ali A; Kumar Y; Akhtar F; Kulanthaivel S; Mishra P; Khan F; Khan AU
    Microbiol Spectr; 2022 Oct; 10(5):e0045022. PubMed ID: 36069578
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Rahman M; Khan MKA
    J Biomol Struct Dyn; 2020 Apr; 38(7):2093-2103. PubMed ID: 31184285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
    Guo Y; Yang Y; Xu X; Li L; Zhou Y; Jia G; Wei L; Yu Q; Wang J
    Eur J Med Chem; 2022 Mar; 231():114108. PubMed ID: 35101651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor and substrate binding by New Delhi metallo-beta-lactamase-1: a molecular dynamics studies.
    Wang YT; Lu CY; Hour TC; Cheng TL
    Curr Comput Aided Drug Des; 2014; 10(3):197-204. PubMed ID: 25479381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.